IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label remdesivir. Show all posts
Showing posts with label remdesivir. Show all posts
Monday, 29 June 2020

Gilead Sciences Releases Letter on Pandemic Pricing of COVID-19 Treatment

›
The Chairman and CEO of Gilead Sciences, Daniel O’Day, has released an open letter concerning the pricing of the COVID-19 treatment remde...
›
Home
View web version
Powered by Blogger.